Biohaven Ltd Dossier - Source-backed chat

Biohaven Ltd

BHVNNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.46

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $13.14Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2B

Enterprise Value $2B

Shares Outstanding 154.6M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Biohaven Ltd. is a high-risk, high-reward clinical-stage biopharmaceutical company transitioning into a pivotal phase with multiple high-impact clinical catalysts scheduled for the second half of 2026. Following strategic portfolio prioritization and R&D optimization, the company is focusing resources on three late-stage platforms: myostatin-activin inhibitors, extracellular protein degraders, and Kv7 ion channel activators. Recent clinical updates from its annual R&D Day in May 2026 have validated its proprietary MoDE and TRAP degrader platforms, demonstrating deep and rapid antibody reductions in Graves' disease and IgA nephropathy. With a solid cash position of $351.8 million as of March 31, 2026, Biohaven is well-funded to reach its near-term milestones, making it a compelling buy for growth-oriented biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$23.07

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case is triggered by clinical trial failures, such as a failure of opakalim to show statistically significant seizure reduction, or safety concerns emerging in the taldefgrobep alfa obesity trial. Additionally, if the biomarker reductions observed in Phase 1b for the degrader platform fail to replicate in pivotal Phase 3 trials, the company's valuation would contract significantly, forcing dilutive capital raises to sustain operations.

Base CaseCentral scenario

The base case assumes successful initiation of pivotal Phase 3 trials for BHV-1300 and BHV-1400 by mid-2026, alongside positive topline readouts for opakalim in focal epilepsy and taldefgrobep alfa in obesity during 2H 2026. These milestones will validate Biohaven's diversified pipeline, driving significant upward re-rating toward consensus analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly diversified clinical-stage pipeline targeting large, high-value markets including epilepsy, obesity, and autoimmune diseases.
Clinically validated extracellular protein degradation platforms (MoDE and TRAP) showing deep, rapid, and selective antibody lowering (over 80% reduction in Graves' disease and 60-70% in IgA nephropathy).
Strong near-term catalyst path with multiple pivotal readouts and trial initiations scheduled for 2H 2026.
Robust balance sheet with $351.8 million in cash and cash equivalents as of Q1 2026, providing runway through critical milestones.

Key Investment Risks

High operational cash burn typical of pre-revenue, clinical-stage biotechnology companies.
Binary clinical trial risk, where negative data readouts for lead assets (opakalim, taldefgrobep alfa) could severely impact valuation.
Regulatory hurdles and potential delays in obtaining FDA approvals or initiating pivotal Phase 3 trials.
Intense competition in key therapeutic areas, particularly in the obesity market dominated by established GLP-1 therapies.

Thesis Invalidation Triggers

Failure of opakalim to meet primary efficacy endpoints in the upcoming Phase 2/3 focal epilepsy trial in 2H 2026.
Inability to initiate or enroll patients in the pivotal Phase 3 trials for BHV-1300 and BHV-1400 by mid-2026.
Severe adverse safety events or high discontinuation rates in the taldefgrobep alfa Phase 2 obesity trial.
Rapid depletion of cash reserves leading to highly dilutive equity financing ahead of key data readouts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.